Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Cancer Resectable × Hydroxychloroquine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 10 Breast Neoplasms 7 Colorectal Neoplasms 6 Prostatic Neoplasms 5 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Multiple Myeloma 3 Gastrointestinal Neoplasms 3 COVID-19 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Solid Tumor 2 Recurrence 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasm Metastasis 2 Melanoma 2 Lung Neoplasms 2 Leukemia 2 Glioblastoma 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Adenocarcinoma of Lung 2 Urologic Diseases 1 Untreated Resectable Pancreatic Adenocarcinoma 1 Sarcoma, Clear Cell 1 Sarcoma 1 Respiratory Distress Syndrome 1 Resectable Localized Prostate Cancer 1

Interventions

Gemcitabine 4 130-nm albumin-bound paclitaxel 2 sintilimab 1 nimotuzumab 1 avelumab 1 Taxes 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Hydroxychloroquine 1 Fluorouracil 1 Capecitabine 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03344172 2020-05-14

17-134

University of Pittsburgh

Phase 2 Terminated

32 enrolled 14 charts

Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡